분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2011-12-03 16:26:22 , Hit : 2661
 Genetic variant linked to development of liver cancer in hepatitis C virus carriers

Public release date: 3-Jul-2011
[ Print | E-mail |  Share ] [ Close Window ]

Contact: Tomoko Ikawa
koho@riken.jp
RIKEN
        

A genome-wide study by researchers at the RIKEN Center for Genomic Medicine, Hiroshima University Hospital and Sapporo-Kosei General Hospital has identified a genetic variant associated with the development of liver cancer in chronic hepatitis C virus carriers. The findings are based on a study of 3,312 Japanese individuals and appear in the journal Nature Genetics.

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is the third leading cancer-related cause of death and the seventh most common form of cancer worldwide. The hepatitis C virus (HVC) is the main risk factor for HCC in many western countries and in Japan, where of the more than 30,000 deaths each year from HCC, 70% involve HVC.

To identify risk factors connecting HVC and HCC, the research group conducted a genome-wide study on a group of 3,312 Japanese individuals carrying the hepatitis C virus. Analyzing a total of 467,538 genetic markers (called single nucleotide polymorphisms or SNPs) in a group of 212 HCV carriers with HCC and 765 HCV carriers without HCC, the group uncovered one SNP associated with HCC risk, located on a gene called DEPDC5. The association was confirmed in an independent replication study on a population of 2335 HVC carriers, 710 with HCC and 1625 without HCC.  
    

The significance of the findings was further highlighted when the researchers adjusted their results for gender, age and platelet count, revealing that among Japanese individuals with chronic HVC infection, the DEPDC5 SNP roughly doubles the odds of developing HCC.

While deepening our understanding of the mechanisms triggering HCC, the discovery of the DEPDC5 SNP locus also provides a valuable target for new therapy techniques, promising progress in the ongoing battle to overcome one of the world's most deadly cancers.








827   Vertex study will evaluate 12-week treatment period for some hepatitis C patients  이성욱 2011/10/25 2884
826   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3641
825   Going Viral  이성욱 2011/10/28 2659
824   GlaxoSmithKline is first partner for new Alnylam platform  이성욱 2011/11/02 2577
823   Do Bacteria Age? Biologists Discover the Answer Follows Simple Economics  이성욱 2011/11/04 2435
822   Regular Aspirin Intake Halves Cancer Risk, Study Finds  이성욱 2011/11/04 2397
821   Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies  이성욱 2011/11/10 2482
820   How Blood Cells Thwart Malaria  이성욱 2011/11/13 3414
819   Pox Vaccine Treats Liver Cancer - Smallpox vaccine extends life in cancer trial-  이성욱 2011/11/13 2685
818   AASLD: African-Americans Face Hep C 'Triple Whammy'  이성욱 2011/11/17 2403
817   Uncovering a Key Player in Metastasis  이성욱 2011/11/21 2608
816   Finger (mal)formation reveals surprise function of desert DNA  이성욱 2011/11/28 2762
815   Stem-cell pioneer bows out  이성욱 2011/11/28 2481
  Genetic variant linked to development of liver cancer in hepatitis C virus carriers  이성욱 2011/12/03 2661
813   Treatment for Blood Disease Is Gene Therapy Landmark  이성욱 2011/12/13 2027
812   Vertex begins joint studies on hepatitis C compounds  이성욱 2011/12/13 2667
811   Former Reginans changing the future of HIV  이성욱 2011/12/28 2306
810   The RNA roots of obesity?  이성욱 2012/01/03 2288
809   Alnylam Cuts One-Third of Workforce, To Save Cash for RNAi Clinical Plans  이성욱 2012/01/22 2485
808   Can DNA Self-replicate?  이성욱 2012/01/22 2491

[이전 10개] [1]..[21][22] 23 [24][25][26][27][28][29][30]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN